Compare Stocks: AVDL, ALKS, LQDA, and LNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$49.40 +0.5%	$49.42	$25.17 ▼ $55.67	$8.25B	0.34	1.76 million shs	1.51 million shs
AVDL Avadel Pharmaceuticals	$21.39 -1.1%	$21.48	$8.19 ▼ $23.57	$2.09B	1.31	2.03 million shs	35.02 million shs
LNTH Lantheus	$100.98 +0.0%	$104.17	$49.67 ▼ $111.86	$6.59B	-0.03	1.70 million shs	1.40 million shs
LQDA Liquidia	$91.03 +0.9%	$77.10	$19.90 ▼ $92.36	$8.02B	0.58	1.31 million shs	1.65 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+0.37%	-5.33%	+38.62%	+84.09%
AVDL Avadel Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+67.76%
LNTH Lantheus	0.00%	+1.31%	-4.44%	+7.31%	+76.49%
LQDA Liquidia	0.00%	+7.26%	+15.77%	+69.81%	+341.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$49.40 +0.5%	$49.42	$25.17 ▼ $55.67	$8.25B	0.34	1.76 million shs	1.51 million shs
AVDL Avadel Pharmaceuticals	$21.39 -1.1%	$21.48	$8.19 ▼ $23.57	$2.09B	1.31	2.03 million shs	35.02 million shs
LNTH Lantheus	$100.98 +0.0%	$104.17	$49.67 ▼ $111.86	$6.59B	-0.03	1.70 million shs	1.40 million shs
LQDA Liquidia	$91.03 +0.9%	$77.10	$19.90 ▼ $92.36	$8.02B	0.58	1.31 million shs	1.65 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+0.37%	-5.33%	+38.62%	+84.09%
AVDL Avadel Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+67.76%
LNTH Lantheus	0.00%	+1.31%	-4.44%	+7.31%	+76.49%
LQDA Liquidia	0.00%	+7.26%	+15.77%	+69.81%	+341.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.72	Moderate Buy	$54.56	10.45% Upside
AVDL Avadel Pharmaceuticals	1.91	Reduce	$20.20	-5.56% Downside
LNTH Lantheus	2.36	Hold	$108.11	7.06% Upside
LQDA Liquidia	2.82	Moderate Buy	$86.18	-5.33% Downside

Current Analyst Ratings Breakdown

Latest AVDL, ALKS, LQDA, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform
8/3/2026	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$125.00 ➝ $102.50
8/3/2026	LNTH Lantheus	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$110.00 ➝ $102.50
8/3/2026	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$102.50
8/3/2026	LNTH Lantheus	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$102.50
8/3/2026	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/3/2026	LNTH Lantheus	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/31/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
7/30/2026	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.67B	4.97	$1.68 per share	29.37	$11.02 per share	4.48
AVDL Avadel Pharmaceuticals	$248.52M	8.41	N/A	N/A	$0.77 per share	27.78
LNTH Lantheus	$1.54B	4.28	$6.39 per share	15.81	$16.43 per share	6.15
LQDA Liquidia	$158.32M	51.13	N/A	N/A	$0.51 per share	178.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	130.00	205.83	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
AVDL Avadel Pharmaceuticals	-$48.83M	N/A	N/A	356.50	N/A	-0.11%	-0.33%	-0.15%	N/A
LNTH Lantheus	$233.56M	$4.14	24.39	18.77	N/A	17.69%	28.10%	14.35%	N/A
LQDA Liquidia	-$68.92M	$0.14	650.26	17.14	N/A	7.74%	46.82%	7.06%	8/12/2026 (Estimated)

Latest AVDL, ALKS, LQDA, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	N/A	N/A	N/A	$168.48 million	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
5/11/2026	Q1 2026	LQDA Liquidia	$0.4102	$0.52	+$0.1098	$0.52	$119.44 million	$132.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
AVDL Avadel Pharmaceuticals	N/A	2.76	2.37
LNTH Lantheus	0.43	3.06	2.89
LQDA Liquidia	1.18	2.22	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
AVDL Avadel Pharmaceuticals	69.19%
LNTH Lantheus	99.06%
LQDA Liquidia	64.54%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
AVDL Avadel Pharmaceuticals	5.20%
LNTH Lantheus	1.70%
LQDA Liquidia	25.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
AVDL Avadel Pharmaceuticals	70	97.66 million	92.58 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
LQDA Liquidia	50	88.93 million	66.16 million	Optionable

AVDL, ALKS, LQDA, and LNTH Headlines

Recent News About These Companies

3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET

August 10 at 10:06 AM | zacks.com

Liquidia Corporation $LQDA Stock Holdings Lifted by The Manufacturers Life Insurance Company

August 10 at 4:40 AM | marketbeat.com

California State Teachers Retirement System Has $2.73 Million Stock Holdings in Liquidia Corporation $LQDA

August 10 at 3:43 AM | marketbeat.com

Bank of America Corp DE Has $86.34 Million Stock Holdings in Liquidia Corporation $LQDA

August 9 at 3:43 AM | marketbeat.com

Liquidia Corporation (NASDAQ:LQDA) Receives Average Recommendation of "Moderate Buy" from Analysts

August 9 at 2:28 AM | americanbankingnews.com

Liquidia Corporation (NASDAQ:LQDA) Receives Average Rating of "Moderate Buy" from Brokerages

August 9 at 2:28 AM | marketbeat.com

FNY Investment Advisers LLC Acquires New Shares in Liquidia Corporation $LQDA

August 7 at 6:47 AM | marketbeat.com

Why Is Liquidia (NASDAQ:LQDA) Drawing Attention Among Smaller Biotech Names?

August 6, 2026 | kalkinemedia.comK

3 Top Ranked Stocks Breaking Out Now

August 5, 2026 | zacks.com

Liquidia (NASDAQ:LQDA) Reaches New 1-Year High - Here's Why

August 5, 2026 | marketbeat.com

Liquidia (LQDA) to Post Quarterly Earnings on Wednesday

August 5, 2026 | marketbeat.com

55,938 Shares in Liquidia Corporation $LQDA Purchased by Segall Bryant & Hamill LLC

August 5, 2026 | marketbeat.com

Sapient Capital LLC Cuts Stock Holdings in Liquidia Corporation $LQDA

August 4, 2026 | marketbeat.com

Empowered Funds LLC Acquires Shares of 96,717 Liquidia Corporation $LQDA

August 4, 2026 | marketbeat.com

Liquidia Corporation $LQDA is Seven Fleet Capital Management LP's 8th Largest Position

August 2, 2026 | marketbeat.com

DV Trading LLC Lowers Position in Liquidia Corporation $LQDA

August 2, 2026 | marketbeat.com

First Trust Advisors LP Sells 27,482 Shares of Liquidia Corporation $LQDA

August 1, 2026 | marketbeat.com

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?

July 31, 2026 | zacks.com

Liquidia (NASDAQ:LQDA) Insider Sells 688 Shares

July 30, 2026 | insidertrades.com

Liquidia (NASDAQ:LQDA) Insider Sells $60,220.64 in Stock

July 29, 2026 | marketbeat.com

Insider Selling: Liquidia (NASDAQ:LQDA) CAO Sells 1,600 Shares of Stock

July 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVDL, ALKS, LQDA, and LNTH Company Descriptions

Alkermes NASDAQ:ALKS

$49.40 +0.23 (+0.47%)

As of 04:00 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals NASDAQ:AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Lantheus NASDAQ:LNTH

$100.98 +0.03 (+0.03%)

As of 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Liquidia NASDAQ:LQDA

$91.03 +0.81 (+0.90%)

As of 04:00 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVDL, ALKS, LQDA, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVDL, ALKS, LQDA, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVDL, ALKS, LQDA, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVDL, ALKS, LQDA, and LNTH Company Descriptions

Alkermes NASDAQ:ALKS

Avadel Pharmaceuticals NASDAQ:AVDL

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVDL, ALKS, LQDA, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVDL, ALKS, LQDA, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVDL, ALKS, LQDA, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVDL, ALKS, LQDA, and LNTH Company Descriptions

Alkermes NASDAQ:ALKS

Avadel Pharmaceuticals NASDAQ:AVDL

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools